Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 159

Sort by

Sort Order Select

Journal Articles

Genomic profiling in CLL patients after BTK inhibitor progression identifies enrichment of mutations in MAPK pathway and epigenetic regulators

Daniel Bihnam, Daniela Trujillo Loaiza, Laura Bruins, Sochilt Brown, Zhiquan Wang, Saad Kenderian, Neil Kay, Sameer Parikh, Esteban Braggio

Blood (2025) 146 (Supplement 1): 5660.

https://doi.org/10.1182/blood-2025-5660

Published: 2025

Journal Articles

Tumor intrinsic mechanisms leading to cevostamab resistance in multiple myeloma

Blood (2025) 146 (Supplement 1): 2178.

https://doi.org/10.1182/blood-2025-2178

Published: 2025

Journal Articles

Genomics define neoplastic transformation in multiple myeloma precursor conditions

Blood (2025) 146 (Supplement 1): 686.

https://doi.org/10.1182/blood-2025-686

Published: 2025

Journal Articles

Targeting lysosomes to overcome albumin-mediated proteasome inhibitor resistance in multiple myeloma

Sinto Chirackal, Gregory Ahmann, Esteban Braggio, Marta Chesi, P. Leif Bergsagel, Rafael Fonseca

Blood (2025) 146 (Supplement 1): 2139.

https://doi.org/10.1182/blood-2025-2139

Published: 2025

Journal Articles

Profiling drug sensitivity in CLL B cells after BTK inhibitor progression using a novel drug panel

Weiguo Han, Emmanuel Contreras Guzman, Aisharya Bhattacharya, Sutapa Sinha, Zhiquan Wang, Kari Rabe, Stephen Anthony, Nathanael Gray, Gerald Crabtree, Esteban Braggio, Saad Kenderian, Sameer Parikh, Neil Kay

Blood (2025) 146 (Supplement 1): 7407.

https://doi.org/10.1182/blood-2025-7407

Published: 2025

Journal Articles

IL-4 epigenetically reprograms CART19-28ζ cells to drive dysfunction

Blood (2025) 146 (Supplement 1): 2338.

https://doi.org/10.1182/blood-2025-2338

Published: 2025

Journal Articles

The predictive value of mosaic chromosomal alterations for lymphoid malignancies varies by monoclonal B-cell lymphocytosis status

Blood (2025) 146 (Supplement 1): 3545.

https://doi.org/10.1182/blood-2025-3545

Published: 2025

Journal Articles

Cyclin D1 beyond the cell cycle: A new role in t(11;14) multiple myeloma

Blood (2025) 146 (Supplement 1): 3939.

https://doi.org/10.1182/blood-2025-3939

Published: 2025

Journal Articles

Venetoclax-obinutuzumab in frontline and R/R CLL: Outcomes compared to age- and sex-matched general population

Blood (2025) 146 (Supplement 1): 3905.

https://doi.org/10.1182/blood-2025-3905

Published: 2025

Journal Articles

Non-CLL-type MBL and chip are associated precursor conditions: Insights from Mayo Clinic's MBL screening cohort

Blood (2025) 146 (Supplement 1): 128.

https://doi.org/10.1182/blood-2025-128

Published: 2025

Journal Articles

Tumor-derived microRNA-125a impairs CART cell function and predicts treatment failure in B cell malignancies

Blood (2025) 146 (Supplement 1): 2321.

https://doi.org/10.1182/blood-2025-2321

Published: 2025

Journal Articles

Progression of disease within 36 months (POD36) of starting first-line targeted therapy independently predicts poor overall survival in patients with chronic lymphocytic leukemia (CLL)

Blood (2025) 146 (Supplement 1): 5667.

https://doi.org/10.1182/blood-2025-5667

Published: 2025

Journal Articles

Biallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myeloma

Blood (2025) 146 (13): 1575–1585.

https://doi.org/10.1182/blood.2024028107

Published: 2025

Includes: Supplemental data

Journal Articles

Incidence and Prevalence of Chronic Lymphocytic Leukemia in the 7-County Region Around Mayo Clinic, Rochester, Minnesota

Bryan A. Vallejo, Sara Achenbach, Kari G. Rabe, Aaron D. Norman, Celine M. Vachon, James R. Cerhan, Esteban Braggio, Susan M. Schwager, Tait D. Shanafelt, Curtis A. Hanson, Sameer A. Parikh, Neil E. Kay, Timothy G. Call, Susan L. Slager

Blood (2024) 144 (Supplement 1): 6801.

https://doi.org/10.1182/blood-2024-209069

Published: 2024

Journal Articles

A Proteogenomic Approach to Identify Potential Drivers of Hyperdiploid Multiple Myeloma

J Erin Wiedmeier-Nutor, Surendra Dasari, Richard Kumaran Kandasamy, Kiran Manalaparthi, Laura Ann Bruins, Gregory Ahmann, Mariano Arribas, P. Leif Bergsagel, Akhilesh Pandey, Esteban Braggio, Rafael Fonseca

Blood (2024) 144 (Supplement 1): 3269.

https://doi.org/10.1182/blood-2024-206239

Published: 2024

Journal Articles

Multi-Omics DNA Methylation Analysis of MYD88 Wild-Type Waldenstrom Macroglobulinemia Reveals Potential Epigenetic Influence on Oncogenic Pathways

Blood (2024) 144 (Supplement 1): 6201.

https://doi.org/10.1182/blood-2024-205509

Published: 2024

Journal Articles

Cyclin D1 Induces Global Epigenetic and Transcriptional Changes in Multiple Myeloma with t(11;14)(q13;q32)

Huihuang Yan, Suganti Shivaram, Hongwei Tang, Hans Anderson, Shulan Tian, Michael D Howe, Abiola Bolarinwa, Cinthya Zepeda Mendoza, Stacey Lehman, Leif Bergsagel, Esteban Braggio, Rafael Fonseca, Shaji Kumar, Francesco Maura, Linda B. Baughn

Blood (2024) 144 (Supplement 1): 6822.

https://doi.org/10.1182/blood-2024-208503

Published: 2024

Journal Articles

The Role of NOXA in Venetoclax Treatment Response in Multiple Myeloma

Blood (2024) 144 (Supplement 1): 4635.

https://doi.org/10.1182/blood-2024-205385

Published: 2024

Journal Articles

Serum Immunoglobulins Are an Independent Prognostic Marker of Time to First Therapy in Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) and Monoclonal B-Cell Lymphocytosis (MBL)

Blood (2024) 144 (Supplement 1): 4616.

https://doi.org/10.1182/blood-2024-194925

Published: 2024

Journal Articles

Genomic Determinants of Clinical Outcomes in Multiple Myeloma with t(11;14)(CCND1;IGH) Treated with Venetoclax

Marcella Kaddoura, J Erin Wiedmeier-Nutor, Vikas A. Gupta, Bachisio Ziccheddu, Suganti Shivaram, Hongwei Tang, Rodrigo Fonseca, Michael Durante, Shannon M Matulis, Tomas Jelinek, Ola Landgren, Constantine S Mitsiades, P. Leif Bergsagel, Esteban Braggio, Lawrence H. Boise, Rafael Fonseca, Shaji Kumar, Francesco Maura, Linda B. Baughn

Blood (2024) 144 (Supplement 1): 249.

https://doi.org/10.1182/blood-2024-204071

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Genomic profiling in CLL patients after BTK inhibitor progression identifies enrichment of mutations in MAPK pathway and epigenetic regulators

Tumor intrinsic mechanisms leading to cevostamab resistance in multiple myeloma

Genomics define neoplastic transformation in multiple myeloma precursor conditions

Targeting lysosomes to overcome albumin-mediated proteasome inhibitor resistance in multiple myeloma

Profiling drug sensitivity in CLL B cells after BTK inhibitor progression using a novel drug panel

IL-4 epigenetically reprograms CART19-28ζ cells to drive dysfunction

The predictive value of mosaic chromosomal alterations for lymphoid malignancies varies by monoclonal B-cell lymphocytosis status

Cyclin D1 beyond the cell cycle: A new role in t(11;14) multiple myeloma

Venetoclax-obinutuzumab in frontline and R/R CLL: Outcomes compared to age- and sex-matched general population

Non-CLL-type MBL and chip are associated precursor conditions: Insights from Mayo Clinic's MBL screening cohort

Tumor-derived microRNA-125a impairs CART cell function and predicts treatment failure in B cell malignancies

Progression of disease within 36 months (POD36) of starting first-line targeted therapy independently predicts poor overall survival in patients with chronic lymphocytic leukemia (CLL)

Biallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myeloma

Incidence and Prevalence of Chronic Lymphocytic Leukemia in the 7-County Region Around Mayo Clinic, Rochester, Minnesota

A Proteogenomic Approach to Identify Potential Drivers of Hyperdiploid Multiple Myeloma

Multi-Omics DNA Methylation Analysis of MYD88 Wild-Type Waldenstrom Macroglobulinemia Reveals Potential Epigenetic Influence on Oncogenic Pathways

Cyclin D1 Induces Global Epigenetic and Transcriptional Changes in Multiple Myeloma with t(11;14)(q13;q32)

The Role of NOXA in Venetoclax Treatment Response in Multiple Myeloma

Serum Immunoglobulins Are an Independent Prognostic Marker of Time to First Therapy in Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) and Monoclonal B-Cell Lymphocytosis (MBL)

Genomic Determinants of Clinical Outcomes in Multiple Myeloma with t(11;14)(CCND1;IGH) Treated with Venetoclax

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only